（ 於 中 華 人 民 共 和 國 註 冊 成 立 的 股 份 有 限 公 司 ） （股份代號：1666） 於二零二六年二月六日（星期五）舉行之 臨時股東會適用之代理人委任表格 本人╱吾等1 地址為 乃北京同仁堂科技發展股份有限公司（「本公司」）股本中每股面值人民幣1.00元之內資股╱ H股3 共 股2 之登記持有人，茲委任臨時股東會主席4 ，或 地址為 為本人╱吾等之代理人，代表本人╱吾等出席本公司謹訂於二零二六年二月六日（星期五）上午九時三十分假座中華人 民共和國（「中國」）北京市豐台區南三環中路20號舉行之臨時股東會（「臨時股東會」）（或其任何續會），藉以考慮並酌情 通過臨時股東會通告（「該通告」）所載之決議案（或經修定），並於臨時股東會（或其任何續會）上以本人╱吾等名義就決 議案按下列指示5 投票。倘無作出指示，則本人╱吾等之委任代理人可自行酌情投票。本人╱吾等之委任代理人亦有權 就該通告所載以外而於臨時股東會上適當提呈之任何事項自行酌情投票。 | | 普通決議案 | 贊成 | 反對 | | --- | --- | --- | --- | | 1. | 批准蕭耀熙先生為本公司第九屆董事會之獨立非執行董 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本通告之內容概不負責，對其準確性或完 整性亦不發表任何聲明，並明確表示概不就因本通告全部或任何部分內容而產生或因依賴該等內容 而引致之任何損失承擔任何責任。 （ 於 中 華 人 民 共 和 國 註 冊 成 立 的 股 份 有 限 公 司 ） （股份代號：1666） 臨時股東會通告 茲通告北京同仁堂科技發展股份有限公司（「本公司」）謹訂於二零二六年二月六日（星 期五）上午九時三十分假座中華人民共和國（「中國」）北京市豐台區南三環中路20號舉行 臨時股東會（「臨時股東會」），藉以考慮及酌情通過下列決議案： 普通決議案 1. 批准蕭耀熙先生為本公司第九屆董事會（「董事會」）之獨立非執行董事及董 事會建議的其薪酬；並授權董事會與其訂立服務合約。 承董事會命 北京同仁堂科技發展股份有限公司 董事長 張毅 1. 出席臨時股東會之資格 於二零二六年二月二日（星期一）名列本公司於香港之H股過戶登記處香港中央證券登記有限公 司存置之股東名冊之H股持有人及名列本公司股東名冊之內資股持有人將有資格出席臨時股東會。 2. 代理人 3. 出席臨時股東會之登記手續 股東或其代理人出席臨時 ...

此乃要件 請即處理 香港交易及結算所有限公司及香港聯合交易所有限公司對本通函之內容概不負責，對其準確性或完 整性亦不發表任何聲明，並明確表示概不會就因本通函全部或任何部分內容而產生或因倚賴該等內 容而引致之任何損失承擔任何責任。 閣下如對本通函任何方面或應採取之行動有任何疑問，應諮詢 閣下之股票經紀或其他註冊證券交 易商、銀行經理、律師、專業會計師或其他專業顧問。 閣下如已將名下之北京同仁堂科技發展股份有限公司股份全部售出或轉讓，應立即將本通函及隨附 之代理人委任表格送交買主或承讓人或經手賣或轉讓之銀行、持牌證券交易商或其他代理商，以便 轉交買主或承讓人。 （ 於 中 華 人 民 共 和 國 註 冊 成 立 的 股 份 有 限 公 司 ） （股份代號：1666） 建議委任董事及釐定董事之薪酬； 及 臨時股東會通告 董事會函件載於本通函第3頁至第6頁。本公司謹訂於二零二六年二月六日（星期五）上午九時三十分 假座中國北京市豐台區南三環中路20號舉行臨時股東會，大會通告載於本通函第7頁至第9頁。 如 閣下擬委任代理人出席臨時股東會，務請儘快且無論如何須於臨時股東會或其任何續會指定舉 行時間24小時前將隨附之代理人委 ...

Core Insights - The article highlights the innovative brand rejuvenation journey of Beijing Tongrentang Technology Development Co., Ltd. at Universal Studios, integrating traditional Chinese medicine with modern cultural tourism [1][12] Group 1: Product Offerings - The company has introduced a new series of health-oriented tea drinks, emphasizing the concept of "food and medicine being of the same origin," which has become a popular choice among consumers [1][5] - Various tea drinks have been developed, including those made from loquat, ginseng, and other medicinal ingredients, showcasing the company's commitment to quality and traditional craftsmanship [3][5] - The "Warm Body Nourishing" loquat ginseng soup has gained traction among consumers during winter, providing warmth and comfort through its carefully selected ingredients [5] Group 2: Marketing and Brand Strategy - A large outdoor 3D screen at the Beijing Universal Avenue pharmacy displays promotional content, enhancing brand interaction with the public through immersive visual effects [9][11] - The 90-square-meter screen utilizes 5K ultra-high-definition resolution and naked-eye 3D technology to effectively communicate brand messages without additional equipment [11] - The company aims to create a transformation ecosystem that combines traditional elements with technological expression and trendy settings, targeting key demographics such as Gen Z and high-net-worth tourists [12] Group 3: Collaborative Initiatives - The collaboration with Universal Studios represents part of the company's broader strategy to integrate traditional Chinese medicine with modern consumer experiences [15] - The company has engaged in partnerships with other renowned brands and educational institutions to foster innovation and cultural integration within the industry [15] - Future plans include further exploration of traditional Chinese medicine resources to develop more health products that meet consumer needs, expanding the company's presence in the health industry [15]

Core Viewpoint - Tong Ren Tang (600085) Technology announced the resignation of Mr. Li Zhaobin as an independent non-executive director and various committee roles effective upon the appointment of a new independent non-executive director at a forthcoming shareholders' meeting [1] Group 1 - Mr. Li Zhaobin applied for resignation due to work changes [1] - The resignation will take effect after the shareholders' meeting selects a new independent non-executive director [1] - The board has proposed the appointment of Mr. Xiao Yaoxi as the new independent non-executive director [1]

格隆汇1月13日丨同仁堂科技(01666.HK)发布公告，2026年1月13日，李兆彬由于工作变动申请辞任独立 非执行董事、审核委员会主席、薪酬委员会委员及战略与规划委员会委员。李兆彬的辞任将自股东于公 司适时召开的股东会上选出新任独立非执行董事起生效。 同日，董事会建议委任萧耀熙为独立非执行董事。根据公司公司章程，该建议委任须待股东于股东会上 批准后方可落实。 ...

Core Viewpoint - Tongrentang Technology (01666) announced the resignation of Mr. Li Zhaobin as an independent non-executive director and various committee roles due to job changes, effective upon the election of a new independent non-executive director at a forthcoming shareholders' meeting [1] Group 1 - Mr. Li Zhaobin will resign from his positions as chairman of the board audit committee, member of the board remuneration committee, and member of the board strategy and planning committee [1] - The resignation is set to take effect on January 13, 2026, following the election of a new independent non-executive director by shareholders [1] - The board has proposed the appointment of Mr. Xiao Yaoxi as the new independent non-executive director [1]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告之內容概不負責，對其 準確性或完整性亦不發表任何聲明，並明確表示，概不就因本公告全部或任何部份內容 而產生或因依賴該等內容而引致之任何損失承擔任何責任。 （ 於中華人民共和國註冊成立的股份有限公司 ） （股份代號：1666） 公告 董事變更 董事會謹此宣佈，於二零二六年一月十三日，李兆彬先生由於工作變動申請辭 任獨立非執行董事、董事會審核委員會主席、董事會薪酬委員會委員及董事會 戰略與規劃委員會委員。李兆彬先生之辭任將自股東於本公司適時召開的股東 會上選出新任獨立非執行董事起生效。 於二零二六年一月十三日，董事會建議委任蕭耀熙先生為獨立非執行董事。根 據本公司公司章程，該建议委任須待股東於股東會上批准後方可落實。 載有有關上述議案詳細資料的本公司通函將適時寄發予股東。 李先生確認其與董事會並無意見分歧，亦無任何與彼辭任有關事宜須敦請香港聯合交易 所有限公司（「香港聯交所」）及股東垂注。 於二零二六年一月十三日，北京同仁堂科技發展股份有限公司（「本公司」）董事（「董 事」）會（「董事會」）接到李兆彬先生（「李先生」）的辭任函，告知董事會李先生 由於工作變動 ...

Core Insights - The event "Entering Tongrentang, Exploring Traditional Chinese Medicine Culture" marks the launch of the "Double Thousand Stores" initiative aimed at reshaping the retail ecosystem of traditional Chinese medicine [1][3] Group 1: Initiative Overview - The "Double Thousand Stores" project, initiated in July 2025, focuses on transforming partner stores from traditional pharmaceutical sales to comprehensive health services, emphasizing "product strength, service strength, and marketing strength" [3] - The initiative aims to empower terminal upgrades through systematic innovation, injecting new development momentum into the century-old brand [1] Group 2: Supply Chain and Digital Transformation - The company implements a resource allocation strategy to prioritize the stable supply and quality control of 29 key product specifications, reinforcing the product foundation for terminal services [6] - One of the highlights of the "Double Thousand Stores" initiative is the introduction of AI-driven health assessment and diagnostic tools, simulating traditional Chinese medicine practices to provide personalized health management solutions [8][9] Group 3: Marketing and Customer Engagement - The company is developing a diverse and replicable event system, including seasonal health festivals and cultural experience days, to enhance customer engagement and promote the principles of scientific health management [11] - These activities aim to create a sustainable consumption loop, fostering customer loyalty and integrating traditional Chinese medicine culture into daily life [11] Group 4: Future Directions - The successful launch of the initiative signifies a transition from top-level design to regional implementation, with plans to collaborate with more quality terminals to share brand resources and build service capabilities [13] - The company aims to write a new chapter in health services, making the wisdom of the century-old brand accessible to a wider audience in the context of revitalizing traditional Chinese medicine [13]

FF301 股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年12月31日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 北京同仁堂科技發展股份有限公司 呈交日期: 2026年1月5日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 其他類別 (請註明) | | 於香港聯交所上市 (註1) | | 否 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | N/A | 說明 | 內資股 | | | | | | | | | 法定/註冊股份數目 | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 652,080,000 RMB | | 1 | RMB | | 652,080,000 | | 增加 / 減少 (-) | | | 0 | | | RMB | | 0 | | 本月底結存 | | | 652,080,000 RMB | | 1 | RMB | | 652,080,000 | | 2. 股份分類 | ...